Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Acute kidney injury
  • Focus Registrational; Therapeutic Use
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 22 Oct 2018 According to a Quark Pharmaceuticals media release,data from this study will be presented at ASN 2018 and AAO 2018 Annual Meetings.
    • 09 Jul 2018 According to a Quark Pharmaceuticals media release, first patient has been dosed.
    • 12 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top